Thermo Fisher Scientific, Inc. vs Abbvie Inc.
TMO vs ABBV — side-by-side comparison from reported financials. TMO leads 6, ABBV leads 5 of 11 comparable metrics.
Thermo Fisher Scientific, Inc.
TMO · Healthcare
$658.02+0.93%Mixed
Abbvie Inc.
ABBV · Healthcare
$276.43+1.47%Mixed
| Metric | TMO | ABBV |
|---|---|---|
| Price | $658.02 | $276.43 |
| Market cap | $243B | $488B |
| Revenue (TTM) | $46.3B | $64.4B |
| Revenue growth | -0.3% | +1.8% |
| Net margin | 15.0% | 9.8% |
| Free cash flow | $7.32B | $18.2B |
| Net cash (debt) | ($29.3B) | ($56.2B) |
| 1-year price return | +23.1% | +19.8% |
| P/E | 34.9 | 77.4 |
| P/E vs own history (cheap-side %) | 24% | 23% |
| Dividend yield | 0.27% | 2.45% |
| Return on equity | 13% | 96% |
| Altman Z-score | — | 2.33 |
| CV checks passed | 10 of 11 | 9 of 11 |
| Employees | 125,000 | 57,000 |
Full résumé-style profiles: TMO CV · ABBV CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.